Pegylated interferon plus optimized weight-based ribavirin dosing negate the influence of weight and body mass index on early viral kinetics and sustained virological response in chronic hepatitis C

Journal of Viral Hepatitis

Volumn 17, Issue 12, 2010, Pages 834-838

  Pattullo, V ^a,b   Ravindran, N C ^c   Mazzulli, T ^d   Wong, D K H ^a   Heathcote, E J ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Division of Gastroenterology   (Australia)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

body mass index; chronic hepatitis C; rapid virological response; sustained virological response; viral kinetics; weight

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ARTICLE; BODY MASS; BODY WEIGHT; DATA BASE; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; LIVER FIBROSIS; LIVER HISTOLOGY; MALE; POLYMERASE CHAIN REACTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUSTAINED VIROLOGICAL RESPONSE; VIROLOGY; VIRUS LOAD;

ANTIVIRAL AGENTS; BODY MASS INDEX; BODY WEIGHT; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 78649249565     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01248.x     Document Type: Article

References (23)

1. Bressler BL, Guindi M, Tomlinson G, Heathcote J,. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38 (3): 639 - 644.
2. Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004; 40 (3): 484 - 490.
3. Walsh MJ, Jonsson JR, Richardson MM, et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006; 55 (4): 529 - 535.
4. Shiffman ML, Salvatore J, Hubbard S, et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007; 46 (2): 371 - 379.
5. Jacobson IM, Brown RS Jr, Freilich B, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007; 46 (4): 971 - 981.
6. Jacobson IM, Brown RS Jr, McCone J, et al. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology 2007; 46 (4): 982 - 990.
7. Fried MW, Jensen DM, Rodriguez-Torres M, et al. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology 2008; 48 (4): 1033 - 1043.
8. Gheorghe L, Iacob S, Sporea I, et al. Efficacy, tolerability and predictive factors for early and sustained virologic response in patients treated with weight-based dosing regimen of PegIFN alpha-2b ribavirin in real-life healthcare setting. J Gastrointestin Liver Dis 2007; 16 (1): 23 - 29.
9. Yu ML, Dai CY, Huang JF, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008; 47 (6): 1884 - 1893.
10. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43 (5): 954 - 960.
11. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43 (3): 425 - 433.
12. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357 (2): 124 - 134.
13. Dalgard O, Bjoro K, Hellum KB, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004; 40 (6): 1260 - 1265.
14. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352 (25): 2609 - 2617.
15. Von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129 (2): 522 - 527.
16. Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40 (6): 993 - 999.
17. Carlsson T, Quist A, Weiland O,. Rapid viral response and treatment outcome in genotype 2 and 3 chronic hepatitis C: comparison between two HCV RNA quantitation methods. J Med Virol 2008; 80 (5): 803 - 807.
18. Dalgard O, Bjoro K, Ring-Larsen H, et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008; 47 (1): 35 - 42.
19. Lagging M, Langeland N, Pedersen C, et al. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 2008; 47 (6): 1837 - 1845.
20. WHO. Obesity: preventing and managing a global epidemic. Report on a WHO Consultation in Obesity, Geneva 3-5 June, 1997. WHO/NUT/NCD/98.1. Technical Report Series Number 894; Geneva: World Health Organization; 2000.
21. Hsu CS, Liu CH, Liu CJ, et al. Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. Antivir Ther 2009; 14 (1): 45 - 54.
22. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135 (2): 451 - 458.
23. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461 (7262): 399 - 401.